Market Cap 394.69B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 23.70
Forward PE 21.03
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 5,972,100
Avg Vol 5,715,906
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 67%
Beta 0.36
Analysts Strong Sell
Price Target $246.08

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
shadowpawn
shadowpawn Dec. 16 at 2:16 AM
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 12:44 AM
$SLS $ABBV is the number one bio tech for AML, they have 5 billion in cash 401B market cap. ABBV dropping 10 bill for two best in class (possible) AML drugs dosent seem unrealistic.
0 · Reply
DeadInvestor
DeadInvestor Dec. 15 at 7:22 PM
$ALDX No idea if this will happen: I predict a 415pm news release, with approval and full label language. Then ALDX indicates $ABBV has exercised their 10-day option. Stock climbs to $15. Current market cap is $250 million. ABBV injection of $194 million should excite things!
3 · Reply
SSmicrocap
SSmicrocap Dec. 15 at 4:59 PM
$ABBV dump time
0 · Reply
Garibs
Garibs Dec. 15 at 2:52 PM
$ABBV don't let them take you red ... had good momentum for 230
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 15 at 1:31 PM
$IFRX $MLTX $ABBV $RHHBY $SNY https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70150 “Despite standardized criteria for patient selection and outcome assessment, placebo response rates continue to demonstrate substantial variability across AD clinical trials. Recent reviews [12-14] report placebo EASI-75 response rates ranging from approximately 12% to over 20% at the primary assessment time points of Week 12 and Week 16. This variability introduces challenges when evaluating the efficacy of novel therapeutic agents, as it can lead to failed studies despite genuine therapeutic benefits by confounding treatment effect estimates with unexpectedly high placebo responses.”
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 15 at 11:05 AM
$ABBV RSI: 30.79, MACD: -0.7212 Vol: 4.12, MA20: 228.43, MA50: 227.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:34 AM
Actionable Trade Alert for $ABBV: Market Context: $ABBV is currently trading at $223.32, showing a bearish sentiment with an RSI of 30.79, indicating oversold conditions. The stock is below both the 30-day MA of 225.96 and the 50-day MA of 227.35, suggesting continued downward pressure. However, the price is near the 60-day low of 211.69, which could present a potential reversal opportunity. Directional Bias: Given the oversold RSI and proximity to the 60-day low, there is a chance for a bullish reversal. Trade Plan: - Suggested Entry: $223.32 - Stop Loss: $210.00 (below the 60D low for risk management) - Take Profit Targets: - TP1: $230.00 (3% gain) - TP2: $240.00 (7.5% gain) - TP3: $260.00 (16.5% gain) With a potential ROI of over 17% on TP3, this trade offers a favorable risk-reward ratio. Monitor the price action closely for confirmation of the bullish reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 11:59 PM
Enter: $ABBV Calls Strike Price: $225 Expiry Date: JAN 09 2026 Buy in Price: $4.95 - $5.40 Sell Price: $7.82 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 14 at 11:20 AM
$ABBV sitting at $223 with slightly lower volume, while $LLY trading at $1028 with even lighter volume. ABBV showing relative strength compared to LLY in the Healthcare sector. Will the sector catalysts push these stocks in opposite directions soon?
0 · Reply
Latest News on ABBV
My Top 3 Healthcare Stocks to Buy in 2026

Dec 13, 2025, 2:37 PM EST - 2 days ago

My Top 3 Healthcare Stocks to Buy in 2026

ISRG LLY


The Smartest Dividend Stocks to Buy With $5,000 Right Now

Dec 12, 2025, 4:00 AM EST - 3 days ago

The Smartest Dividend Stocks to Buy With $5,000 Right Now

BAC EPD


Is AbbVie Stock Too Cheap to Ignore at Today's Price?

Dec 11, 2025, 11:06 AM EST - 4 days ago

Is AbbVie Stock Too Cheap to Ignore at Today's Price?


AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 5 days ago

AbbVie: Unique Mix Of Growth And Value


3 Top Dividend Stocks to Buy in December

Dec 9, 2025, 4:44 AM EST - 6 days ago

3 Top Dividend Stocks to Buy in December

ARCC ENB


Could Buying AbbVie Today Set You Up for Life?

Dec 4, 2025, 9:15 AM EST - 11 days ago

Could Buying AbbVie Today Set You Up for Life?


2 Top Dividend Stocks to Buy Now and Hold For a Decade

Dec 2, 2025, 7:44 AM EST - 13 days ago

2 Top Dividend Stocks to Buy Now and Hold For a Decade

PFE


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 16 days ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


8 Dividend Stocks Every Investor Should Consider

Nov 28, 2025, 5:30 AM EST - 17 days ago

8 Dividend Stocks Every Investor Should Consider

AXP COST JPM NVDA PFE PM SPGI


5 Dividend Stocks to Hold for the Next 10 Years

Nov 24, 2025, 7:25 AM EST - 21 days ago

5 Dividend Stocks to Hold for the Next 10 Years

ARCC ENB O VZ


AbbVie Stock Falls 4% -- What Investors Need to Know

Nov 17, 2025, 7:17 AM EST - 4 weeks ago

AbbVie Stock Falls 4% -- What Investors Need to Know


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

JNJ


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 4 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 4 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Three Healthcare Buys That Wall Street Loves

Nov 11, 2025, 10:50 AM EST - 4 weeks ago

Three Healthcare Buys That Wall Street Loves

AMGN LLY


5 Top Stocks to Buy in November

Nov 11, 2025, 8:49 AM EST - 4 weeks ago

5 Top Stocks to Buy in November


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 5 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

Nov 6, 2025, 8:45 AM EST - 5 weeks ago

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

CL ZTS


My Favorite Dividend King to Buy in November

Nov 3, 2025, 7:30 AM EST - 6 weeks ago

My Favorite Dividend King to Buy in November


2 Magnificent Dividend Stocks to Buy and Hold Forever

Nov 2, 2025, 9:15 AM EST - 6 weeks ago

2 Magnificent Dividend Stocks to Buy and Hold Forever

ZTS


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 6 weeks ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


Why AbbVie Stock Flopped on Friday

Nov 1, 2025, 6:15 AM EDT - 6 weeks ago

Why AbbVie Stock Flopped on Friday


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 6 weeks ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


shadowpawn
shadowpawn Dec. 16 at 2:16 AM
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 12:44 AM
$SLS $ABBV is the number one bio tech for AML, they have 5 billion in cash 401B market cap. ABBV dropping 10 bill for two best in class (possible) AML drugs dosent seem unrealistic.
0 · Reply
DeadInvestor
DeadInvestor Dec. 15 at 7:22 PM
$ALDX No idea if this will happen: I predict a 415pm news release, with approval and full label language. Then ALDX indicates $ABBV has exercised their 10-day option. Stock climbs to $15. Current market cap is $250 million. ABBV injection of $194 million should excite things!
3 · Reply
SSmicrocap
SSmicrocap Dec. 15 at 4:59 PM
$ABBV dump time
0 · Reply
Garibs
Garibs Dec. 15 at 2:52 PM
$ABBV don't let them take you red ... had good momentum for 230
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 15 at 1:31 PM
$IFRX $MLTX $ABBV $RHHBY $SNY https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70150 “Despite standardized criteria for patient selection and outcome assessment, placebo response rates continue to demonstrate substantial variability across AD clinical trials. Recent reviews [12-14] report placebo EASI-75 response rates ranging from approximately 12% to over 20% at the primary assessment time points of Week 12 and Week 16. This variability introduces challenges when evaluating the efficacy of novel therapeutic agents, as it can lead to failed studies despite genuine therapeutic benefits by confounding treatment effect estimates with unexpectedly high placebo responses.”
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 15 at 11:05 AM
$ABBV RSI: 30.79, MACD: -0.7212 Vol: 4.12, MA20: 228.43, MA50: 227.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:34 AM
Actionable Trade Alert for $ABBV: Market Context: $ABBV is currently trading at $223.32, showing a bearish sentiment with an RSI of 30.79, indicating oversold conditions. The stock is below both the 30-day MA of 225.96 and the 50-day MA of 227.35, suggesting continued downward pressure. However, the price is near the 60-day low of 211.69, which could present a potential reversal opportunity. Directional Bias: Given the oversold RSI and proximity to the 60-day low, there is a chance for a bullish reversal. Trade Plan: - Suggested Entry: $223.32 - Stop Loss: $210.00 (below the 60D low for risk management) - Take Profit Targets: - TP1: $230.00 (3% gain) - TP2: $240.00 (7.5% gain) - TP3: $260.00 (16.5% gain) With a potential ROI of over 17% on TP3, this trade offers a favorable risk-reward ratio. Monitor the price action closely for confirmation of the bullish reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 11:59 PM
Enter: $ABBV Calls Strike Price: $225 Expiry Date: JAN 09 2026 Buy in Price: $4.95 - $5.40 Sell Price: $7.82 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 14 at 11:20 AM
$ABBV sitting at $223 with slightly lower volume, while $LLY trading at $1028 with even lighter volume. ABBV showing relative strength compared to LLY in the Healthcare sector. Will the sector catalysts push these stocks in opposite directions soon?
0 · Reply
TradeWoFear
TradeWoFear Dec. 14 at 12:58 AM
$ABBV Looks like close tie !! Forecasted by CNN!!! i will leave the guess to you!!!
0 · Reply
lextrading
lextrading Dec. 13 at 6:11 PM
$ABBV RFK Jr. has signaled interest in loosening regulations around testosterone replacement therapy. AbbVie (ABBV), the leading manufacturer of AndroGel, could stand to benefit from any expansion in market access. However, shares are currently trading near a well-defined resistance trendline. I will be monitoring price action closely for signs of rejection and a potential move lower toward established support levels.
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Dec. 12 at 11:07 PM
$ABBV rotation? Hello!?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 9:57 PM
Enter: $ABBV Calls Strike Price: $225 Expiry Date: JAN 02 2026 Buy in Price: $6.00 - $6.70 Sell Price: $13.74 Profit : +129% (Turn every $1 into $2.29) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
RodTownsend
RodTownsend Dec. 12 at 8:12 PM
$ABBV diversified pharma pipeline depth and defensive cash-flow feel like a steady anchor for rotation money
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 12 at 5:29 PM
$SLS Does everyone understand the BEST AVAILABLE TREATMENT for the CONTROL ARM Patients is TOXIC As F??? in the VIALE- A Trial - 83% suffer Serious Side Effects, and 23% DIED ... DIED from Taking AzaVEN. $ABBV Terminated the VIALE-M Maintenance Trial for AML Patients in First Remission - even with multiple reduced dosing schedules - its not effective Maintenance for CR1 Patients, its going to be worse for CR2. - Just like all the KOL's have STATED - BAT is toxic, MOS is Dismal, extremely poor, not durable - actual QUOTES, just 6 month, 6-8 months, 5-7 months with AZA VEN.
0 · Reply
Garibs
Garibs Dec. 12 at 5:12 PM
$ABBV another price target increase.. you guys know what that means, another drop 🤦‍♂️ this should be at least 240
1 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:00 PM
Morgan Stanley has adjusted their stance on AbbVie ( $ABBV ), setting the rating to Overweight with a target price of 261 → 269.
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 3:37 PM
$ABBV just cracked its 50-day SMA — opportunity or trap? 👀 Immunology momentum is still running strong, and the long-term trend is described as resilient even with the dip below that key level. Full breakdown on how to play ABBV 👉 https://www.zacks.com/stock/news/2803475/abbvie-slipped-below-50-day-sma-last-week-how-to-play-the-stock?cid=sm-stocktwits-2-2803475-teaser-24591&ADID=SYND_STOCKTWITS_TWEET_2_2803475_TEASER_24591
0 · Reply
Garibs
Garibs Dec. 12 at 3:01 PM
$ABBV of course same thing every morning.. something's going on here
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 2:37 PM
$ABBV slipping below its 50-day SMA — time to worry or hold steady? 🤔 Despite recent dips, ABBV is still riding a strong long-term trend with its ex-Humira platform driving over 20% sales growth in ex-Humira drugs last quarter, fueled by Skyrizi and Rinvoq. 📈 Find out why staying invested could be smart here 👉 https://www.zacks.com/stock/news/2803475/abbvie-slipped-below-50-day-sma-last-week-how-to-play-the-stock?cid=sm-stocktwits-2-2803475-body-24581&ADID=SYND_STOCKTWITS_TWEET_2_2803475_BODY_24581
0 · Reply
RodTownsend
RodTownsend Dec. 12 at 1:24 PM
$ABBV I’m comfortable holding AbbVie for defensive biotech exposure given pipeline depth and steady cash dynamics
0 · Reply